Health · 2 views
Certain Myasthenia Gravis Patients May Need More Time to Respond to Efgartigimod
(MedPage Today) -- Intravenous efgartigimod (Vyvgart) continued to show efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies, according to open-label…
Summary
(MedPage Today) -- Intravenous efgartigimod (Vyvgart) continued to show efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies, according to open-label data from
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- IDSA: Earlier introduction of HPV vaccine improves initiation, completion by age 13Continue reading
- The Ebola outbreak is breaking records -- and just marked a grim milestoneContinue reading
- Pathology research identifies potential new target for preventing brain metastasisContinue reading
- Novel HDAC Inhibitor Hits Main Goal in Unresectable Melanoma TrialContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow